Ceftolozane-tazobactam versus levofloxacin in urinary tract infection - Authors' reply

Affiliations

¹ Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University, Giessen 35392, Germany. Electronic address: florian.wagenlehner@chiru.med.uni-giessen.de.
² Merck Sharp and Dohme/Cubist Pharmaceuticals, Lexington, MA, USA.
³ Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA.

Comment

Florian M Wagenlehner et al. Lancet. 2015.

. 2015 Sep 26;386(10000):1242.

doi: 10.1016/S0140-6736(15)00263-9.

¹ Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University, Giessen 35392, Germany. Electronic address: florian.wagenlehner@chiru.med.uni-giessen.de.
² Merck Sharp and Dohme/Cubist Pharmaceuticals, Lexington, MA, USA.
³ Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA.

No abstract available

Comment on

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Wagenlehner FM, et al. Lancet. 2015 May 16;385(9981):1949-56. doi: 10.1016/S0140-6736(14)62220-0. Epub 2015 Apr 27. Lancet. 2015. PMID: 25931244 Clinical Trial.
Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Boyles T. Boyles T. Lancet. 2015 Sep 26;386(10000):1241. doi: 10.1016/S0140-6736(15)00260-3. Lancet. 2015. PMID: 26460655 No abstract available.
Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Kielstein JT, Schmidt JJ. Kielstein JT, et al. Lancet. 2015 Sep 26;386(10000):1241. doi: 10.1016/S0140-6736(15)00261-5. Lancet. 2015. PMID: 26460656 No abstract available.
Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Popa C, Mircheva M, Krämer BK, Berghofen A, Krüger B. Popa C, et al. Lancet. 2015 Sep 26;386(10000):1241-1242. doi: 10.1016/S0140-6736(15)00262-7. Lancet. 2015. PMID: 26460657 No abstract available.